Raju Prasad, Ph.D.

Raju Prasad, Ph.D.

Chief Financial OfficeratCRISPR Therapeutics AG· In proxies 2023–2025

Pay in FY2025-35% from the year before · CRISPR Therapeutics AG stock +33.2% the same year

Raju Prasad, Ph.D. was paid $3.6M in FY2025 (Dec), down 35%. CRISPR Therapeutics AG stock rose 33.2% that year.

Pay$100 in the stock at the end of FY22 → $129
Pay is from the Summary Compensation Table of each CRISPR Therapeutics AG proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. CRISPR Therapeutics AGPublic company · 3 yr
    • Chief Financial Officer2023 – Present · 3 yrStock in role +32%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?